Sunday, December 25, 2016 6:17:43 PM
I see people on this board who do not understand the science at all but look at the Press Releases as some major announcement. For HYSR, nothing is further from the truth. The most recent PR basically stated that they had achieved ~1.6V, new prototypes to allow larger production, etc. etc. While all of those claims are probably factual, they are totally irrelevant! Yet that generated the buying of shares.
It does not matter one iota that HYSR has a prototype, has raised the voltage to whatever and so on. Even if they actually achieved voltages of 5V !!! all that is meaningless, unless:
The cost of the particles that produce the H2 makes them commercially viable. As an exaggerated example, if it costs $10 to manufacture (on any scale) particles with any voltage capacity that produce a sufficient amount of H2 that sells for only $1, everything else is irrelevant! The actual cost of the particles must be far less than the revenue generated from the H2 they produce! Some people here seem to miss that.
To the point, Time Young's press releases have consistently acknowledged the "challenges" facing commercial production, many readers of that PR just assume that to be a trivial step when, in fact, it might be a non-achievable one (and probably is). That is quite likely why big companies have not yet jumped on board.
Recent HYSR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:31:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/02/2024 05:15:09 AM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 01/25/2024 09:40:59 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/24/2024 09:32:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 08:28:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2023 09:03:04 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/29/2023 08:33:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2023 08:13:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM